Alzamend Neuro raises $7.5 million in unregistered sale of Series D convertible preferred stock to Ault Lending

• Alzamend Neuro closed a $7.5 million private placement with Ault Lending via Series D Convertible Preferred Stock.
• Deal targets up to $25 million across 17 tranches; includes up to $17.5 million of additional funding for clinical programs, working capital.
• Initial tranche sold 7,500 preferred shares at $1,000 each; stated value $1,050 per share.
• Next $2.5 million tranche expected within 10 business days of SEC effectiveness for a resale registration covering conversion shares.
• Remaining $15 million slated as monthly $1 million tranches over about 15 months; 2% origination fee due per closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF18701) on August 04, 2026, and is solely responsible for the information contained therein.